Comparison of the Efficacy of Sintilimab and Apatinib in the Treatment of Patients with Recurrent Advanced Esophageal Cancer
Objective:To investigate the effect of Sintilimab in the treatment of patients with recurrent advanced esophageal cancer and its effect on the levels of tumor markers,neuron-specific enolase(NSE)and vascular endothelial growth factor(VEGF).Methods:From July 2020 to July 2022,43 patients with recurrent advanced esophageal cancer who were admitted to Tongxu First Hospital for treatment with Sindili monoclonal antibody were selected as the experimental group.At the same time,43 patients with recurrent advanced esophageal cancer who were admitted to our hospital for treatment with apatinib from September 2018 to December 2019 were retrospectively selected as the control group.The clinical efficacy,tumor marker level,tumor cytokine concentration and toxic and side effects were compared between the two groups.Results:The DCR and ORR of the experimental group were higher than those of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CYFRA21-1,SCC,NSE and VEGF in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of toxic and side effects between the experimental group and the control group(P>0.05).Conclusion:The treatment of Sindilimab is helpful to reduce the levels of tumor markers and tumor cytokine concentrations in patients with recurrent advanced esophageal cancer,enhance the clinical efficacy,and has certain safety.
NETL
NSTL
万方数据
